Research programme: small molecule therapeutics - Gain Therapeutics
Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Gain Therapeutics
- Developer Gain Therapeutics; Institute for Research in Biomedicine; Neurocentro
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Glucosylceramidase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Gangliosidoses; Gaucher's disease; Mucopolysaccharidosis IV; Parkinson's disease
- No development reported Lysosomal storage diseases; Neurodegenerative disorders
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for research development in Lysosomal storage diseases in Switzerland (PO, Pill)
- 28 Jan 2025 No recent reports of development identified for research development in Neurodegenerative-disorders in Switzerland (Pill)
- 15 Mar 2022 Preclinical trials in Alzheimer's disease in Switzerland (PO) before March 2022